Testing effectiveness (Phase 2)UnknownNCT03903887What this trial is testingAnti-PD1 Antibody-activated TILs in Non-small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer Sun Yat-sen University 20
Early research (Phase 1)Looking for participantsNCT06469281What this trial is testingLearn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersWho this might be right forEpithelial Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer Regeneron Pharmaceuticals 90
Testing effectiveness (Phase 2)Looking for participantsNCT05086692What this trial is testingA Beta-only IL-2 ImmunoTherapY StudyWho this might be right forAdvanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more Medicenna Therapeutics, Inc. 115
Testing effectiveness (Phase 2)UnknownNCT02081937What this trial is testingCART-19 Immunotherapy in Mantle Cell LymphomaWho this might be right forHematopoietic/Lymphoid CancerNon-hodgkin Lymphoma,B CellMantle Cell Lymphoma Chinese PLA General Hospital 2
Testing effectiveness (Phase 2)UnknownNCT03736330What this trial is testingAnti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal CarcinomaWho this might be right forRenal Cancer Metastatic Sun Yat-sen University 24
Testing effectiveness (Phase 2)WithdrawnNCT03167177What this trial is testingQUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWho this might be right forMelanoma ImmunityBio, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT07281924What this trial is testingHepzato Kit and Opdualag for Metastatic Melanoma and Liver MetastasisWho this might be right forMetastatic MelanomaLiver Metastases University of Wisconsin, Madison 15
Early research (Phase 1)Study completedNCT01137006What this trial is testingAn Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant MelanomaWho this might be right forMalignant Melanoma Eli Lilly and Company 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT02422381What this trial is testingMK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)Who this might be right forCarcinoma, Non-Small-Cell Lung Providence Health & Services 16
Testing effectiveness (Phase 2)Study completedNCT03623646What this trial is testingCisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.Who this might be right forOropharyngeal Squamous Cell Carcinoma Institut Claudius Regaud 11
Early research (Phase 1)Study completedNCT04306900What this trial is testingTTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced CancersWho this might be right forSolid Tumor, Adult Trishula Therapeutics, Inc. 185
Testing effectiveness (Phase 2)Looking for participantsNCT07230613What this trial is testingNeo-adjuvant Immunotherapy in Patients With Localized MelanomaWho this might be right forCutaneous Melanoma, Stage IIIMucosal Melanoma UNICANCER 50
Testing effectiveness (Phase 2)Looking for participantsNCT06170710What this trial is testingPostoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCCWho this might be right forHead and Neck Squamous Cell Carcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences 173
Early research (Phase 1)Active Not RecruitingNCT02715284What this trial is testingStudy of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid TumorsWho this might be right forNeoplasms Tesaro, Inc. 730
Very early researchLooking for participantsNCT06765876What this trial is testingCART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I TrialWho this might be right forLeukemia, Myeloid, Acute(AML)Precursor Cell Lymphoblastic Leukemia-LymphomaMyelodysplastic Syndromes (MDS)+1 more Institute of Hematology and Blood Transfusion, Czech Republic 18
Testing effectiveness (Phase 2)Study completedNCT03989362What this trial is testingVopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial CancerWho this might be right forCancer Jounce Therapeutics, Inc. 61
Not applicableActive Not RecruitingNCT05364086What this trial is testingAn Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT StudyWho this might be right forHematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm University of Rochester NCORP Research Base 2,100
Testing effectiveness (Phase 2)Study completedNCT03525678What this trial is testingInvestigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 AntibodyWho this might be right forMultiple Myeloma GlaxoSmithKline 221
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07022301What this trial is testingSintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 TherapyWho this might be right forSmall Cell Lung Cancer Extensive StageResistance to Immunotherapy First Affiliated Hospital of Wannan Medical College 25
Early research (Phase 1)Looking for participantsNCT05298995What this trial is testingGD2-CAR T Cells for Pediatric Brain TumoursWho this might be right forBrain Tumor, PediatricMedulloblastoma, ChildhoodEmbryonal Tumor+4 more Bambino Gesù Hospital and Research Institute 54